Would you have Sweating - Excessive when you have Multiple Sclerosis?


Sweating - excessive is found among people with Multiple sclerosis, especially for people who are female, 50-59 old, take medication Avonex and have Depression. We study 2,617 people who have Sweating - excessive and Multiple sclerosis from FDA and social media. Find out below who they are, other conditions they have and drugs they take.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>

Multiple Sclerosis

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) can be treated by Copaxone, Tysabri, Avonex, Rebif, Baclofen (latest reports from 423,460 Multiple sclerosis patients)

Sweating - Excessive

Sweating - excessive has been reported by people with depression, pain, high blood pressure, multiple sclerosis, rheumatoid arthritis (latest reports from 68,757 Sweating - excessive patients).

On Oct, 20, 2016

2,617 people who have Multiple Sclerosis and Sweating - Excessive are studied.

Number of reports submitted per year:

Would you have Sweating - excessive when you have Multiple sclerosis?

Gender of people who have Multiple Sclerosis and experience Sweating - Excessive *:

  • female: 75.13 %
  • male: 24.87 %

Age of people who have Multiple Sclerosis and experience Sweating - Excessive *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.65 %
  • 20-29: 5.58 %
  • 30-39: 18.25 %
  • 40-49: 30.18 %
  • 50-59: 30.69 %
  • 60+: 14.65 %

Severity of Sweating - Excessive *:

  • least: 0.0 %
  • moderate: 25 %
  • severe: 25 %
  • most severe: 50 %

Top co-existing conditions for these people *:

  • Depression (56 people, 2.14%)
  • Pain (50 people, 1.91%)
  • Gait Disturbance (46 people, 1.76%)
  • Hypertension (44 people, 1.68%)
  • Anxiety (27 people, 1.03%)

Most common drugs for these people *:

  • Avonex (773 people, 29.54%)
  • Tysabri (478 people, 18.27%)
  • Tecfidera (405 people, 15.48%)
  • Rebif (295 people, 11.27%)
  • Gilenya (199 people, 7.60%)

Top symptoms for these people *:

  • Nausea (568 people, 21.70%)
  • Fatigue (513 people, 19.60%)
  • Chills (457 people, 17.46%)
  • Headache (452 people, 17.27%)
  • Pain (354 people, 13.53%)

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Sweating - excessive and Multiple sclerosis?

Browse all symptoms of Multiple sclerosis

a b c d e f g h i j k l m n o p q r s t u v w x y z

Could your drugs cause Sweating - excessive

Sweating - excessive

Other conditions that could case Sweating - excessive

Sweating - excessive

Related studies

Can you answer these questions?

More questions for: Multiple sclerosis, Sweating - excessive

You may be interested in these reviews

More reviews for: Multiple sclerosis, Sweating - excessive

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.